New Research Unveils p53 Aggregates’ Vital Role in Ovarian Cancer Prognosis and Treatment Strategies
The authors used the NaveniFlex™ assay and we are proud our research tools proved to be of great importance in ovarian cancer research.
CICON-23, 20-23 September, Milan Italy
Come and meet Navinci’s Doroteya Raykova and Inge Cyrén at the CICON-23 Conference in Milan, Italy, 20-23 September.
Expanding Your Options with NaveniLink™
Would you like to perform a proximity ligation assay using your own primary antibodies? Our NaveniLink conjugation kit allows you to do just that.
Product Advancement: NaveniFlex™ Cell
This cutting-edge kit is meticulously fine-tuned for in situ cell analysis and delivers enhanced signal strength, a shorter protocol including a separate protocol for 96-well plates.
NaveniFlex in Autophagy publication
Naveni® technology has been referenced in a publication describing novel insights into the process of lysosomal degradation of mitochondria.
Cayman and Navinci Announce Strategic Partnership
Cayman and Navinci Announce Strategic Partnership Expanding Access to Next-Generation Tools for Spatial Proteomics Ann Arbor, MI – 07/05/2023 – Global life sciences supplier Cayman Chemical (Cayman) announced today a strategic partnership with Navinci Diagnostics (Navinci), a Swedish biotechnology company developing innovative tools for spatial proteomics. This partnership expands access to Navinci’s portfolio of proximity…
Navinci Diagnostics AB announces closing of SEK 90M Series A financing, led by Segulah Medical Acceleration with support from existing shareholders
Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of a SEK 90 million financing round. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.…
The importance of specific protein detection in ACE2 localization studies
Correct localization of proteins is critical for both the understanding and treatment of many diseases. High specificity immunoassays are of particular value for precision diagnostics use and in large-scale therapeutics development. The quality of these in situ protein detection assays depends mainly on the antibodies’ specificity against the target. Many commercial antibodies have low specificity,…
Detect phosphorylation with NaveniFlex proximity ligation
Protein phosphorylation has been the target of many drugs, both approved and under development, as well as diagnostics. Phosphorylation status lies beyond the capability of transcriptomics or genomics and is commonly addressed with antibody-based techniques. Most commercially available phospho-antibodies show a moderate-to-high lack of both specificity and sensitivity in immunostainings. It results in generating false-positive…